Cell-dependent regulation of vasculogenic mimicry by carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1).
CEACAM1
CEACAM1, carcinoembryonic antigen cell adhesion molecule 1
Cell migration
Cell proliferation
DMEM, Dulbecco's modified Eagle's medium
Fibrosarcoma
Melanoma
PBS, phosphate-buffered saline
SDS, sodium dodecyl sulfate
VM, vasculogenic mimicry
Vasculogenic mimicry
Journal
Biochemistry and biophysics reports
ISSN: 2405-5808
Titre abrégé: Biochem Biophys Rep
Pays: Netherlands
ID NLM: 101660999
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
received:
11
01
2020
revised:
18
01
2020
accepted:
20
01
2020
entrez:
7
2
2020
pubmed:
7
2
2020
medline:
7
2
2020
Statut:
epublish
Résumé
Vasculogenic mimicry (VM) promotes tumor migration, metastasis, and invasion in various types of cancer, but the relationship between VM and these phenotypes remains undefined. In this study, we examined carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1) as a novel target of VM. We found that ectopic expression of CEACAM1 in HT1080 human fibrosarcoma cells suppressed the formation of a VM-like network. Further, cell migration and proliferation were abated by the introduction of CEACAM1 into HT1080 cells. Conversely, knockout (KO) of the CEACAM1 gene in SK-MEL-28 melanoma cells, which normally express high levels of CEACAM1, inhibited formation of a VM-like network, which was covered on reintroduction of CEACAM1. These results suggest that CEACAM1 differentially regulates formation of the VM-like network between cancer cell types and implicate CEACAM1 as a novel therapeutic target in malignant cancer.
Identifiants
pubmed: 32025578
doi: 10.1016/j.bbrep.2020.100734
pii: S2405-5808(20)30018-2
pii: 100734
pmc: PMC6997815
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100734Informations de copyright
© 2020 The Authors.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Cancer Metastasis Rev. 2015 Jun;34(2):347-57
pubmed: 26081722
Med Oncol. 2011 Dec;28 Suppl 1:S228-38
pubmed: 20957524
FEBS Lett. 2015 Mar 12;589(6):738-43
pubmed: 25680527
Oncogene. 2006 Aug 17;25(36):4965-74
pubmed: 16568082
Curr Opin Cell Biol. 1997 Oct;9(5):616-26
pubmed: 9330864
Am J Pathol. 2000 Feb;156(2):361-81
pubmed: 10666364
Sci Rep. 2017 Oct 25;7(1):13996
pubmed: 29070803
Biochem Biophys Res Commun. 1992 Jul 31;186(2):881-7
pubmed: 1497672
J Huazhong Univ Sci Technolog Med Sci. 2012 Jun;32(3):346-352
pubmed: 22684556
Biochem Biophys Res Commun. 2017 Oct 21;492(3):447-452
pubmed: 28842255
Mol Cancer Ther. 2015 Jul;14(7):1582-90
pubmed: 25934709
Cancer Sci. 2018 Aug;109(8):2490-2496
pubmed: 29900640
Life Sci. 2007 Jul 4;81(4):336-45
pubmed: 17612570
Bioorg Med Chem Lett. 2017 Oct 1;27(19):4536-4539
pubmed: 28888819
Oncogene. 2011 Oct 13;30(41):4275-88
pubmed: 21532628
Sci Rep. 2016 Nov 21;6:37534
pubmed: 27869227
Cancer Res. 2015 May 1;75(9):1897-907
pubmed: 25744717
FEBS Lett. 2012 May 21;586(10):1504-9
pubmed: 22673517
Biomed Res Int. 2014;2014:803914
pubmed: 24864260
Am J Pathol. 2004 Nov;165(5):1781-7
pubmed: 15509546
J Exp Clin Cancer Res. 2017 Apr 27;36(1):60
pubmed: 28449718
Lung Cancer. 2008 Jun;60(3):426-33
pubmed: 18215438
Cancer Res. 2007 Aug 15;67(16):7841-9
pubmed: 17699790
Acta Biochim Biophys Sin (Shanghai). 2015 Oct;47(10):788-94
pubmed: 26341981
Lab Invest. 1966 Feb;15(2):464-78
pubmed: 5932611
Oncol Lett. 2017 Oct;14(4):4758-4766
pubmed: 29085477
Pathol Oncol Res. 2011 Mar;17(1):67-74
pubmed: 20524097
Cell Physiol Biochem. 2018;45(4):1631-1640
pubmed: 29486474
Oncotarget. 2016 May 24;7(21):30166-77
pubmed: 26885752
Chem Biol. 2004 Mar;11(3):367-77
pubmed: 15123266
Oncotarget. 2016 Apr 26;7(17):24050-62
pubmed: 26992227
FEBS Lett. 2015 Oct 24;589(21):3287-93
pubmed: 26424659
Exp Cell Res. 1998 Jan 10;238(1):197-203
pubmed: 9457072
Nat Commun. 2016 Nov 09;7:13322
pubmed: 27827359
Lung Cancer. 2008 Jun;60(3):309-12
pubmed: 18462829